The Cancer Biology and Genetics (CBG) Program is on a quest to catalyze mechanism-driven science and foster paradigm-shifting cancer concepts. Our labs pursue research bridging basic and clinical cancer science with the goal of improving diagnosis, treatment, and prevention. Our multidisciplinary approach spans areas such as tumor progression and metastasis, tumor microenvironment, mechanisms of drug sensitivity and resistance, and epigenetic sources of tumorigenic traits.
We draw from fundamental mechanisms of cell and tissue development and homeostasis, animal models of disease, and clinical samples in order to enhance our understanding of the biological processes relevant to cancer and to produce or validate new targets that might form the basis of new drugs or therapeutic approaches. Our close alliances with clinicians place us in a unique position, allowing the CBG Program to expedite translational research and make a significant impact on patient care.
- Tuomas Tammela, MD, PhD
Cancer biologist Tuomas Tammela investigates cellular heterogeneity in lung, pancreatic and colon cancers.
- Craig B. Thompson, MD
Memorial Sloan Kettering President Craig Thompson studies molecular signaling pathways that regulate nutrient uptake and the role these pathways play in the regulation of cell growth and survival.
- Andrea Ventura, MD, PhD
Cancer biologist Andrea Ventura studies non-coding RNAs in cancer and development
- Hans-Guido Wendel, MD
Cancer biologist Hans-Guido Wendel pursues both disease-centered and basic discovery research. The disease focus is on lymphocyte malignancies and the basic science arm of the lab explores fundamental mechanisms that control aberrant mRNA translation programs in cancer. Work in these two research areas frequently intersects in surprising ways.
- Richard White, MD, PhD
Cancer biologist and oncologist Richard White uses the zebrafish to dissect interactions between tumor cells and the microenvironment that promote metastasis.
- Elli Papaemmanuil, PhD
Molecular geneticist Elli Papaemmanuil performs systematic interrogations of well annotated clinical trial cohorts in leukemia and cancer to explore how the compound genetic and clonal architecture in patients leukemias and tumors dictate clinical phenotype, disease progression and clinical outcomes.
Collaborations & Resources
SKI offers a wide array of core facilities and other technologies, as well as significant opportunity for collaboration. Scientists in the CBG Program derive particular benefit from close ties to the following: